Associated Papers
The Mutation Patterns of MET Gene in Lung Cancer and Brain Tumors: Clinical and Therapeutic Implications.
Zhang Y et al.
Cancer Medicine, 2026
Autoregulation of the MET receptor tyrosine kinase by its intracellular juxtamembrane domain.
Linossi EM et al.
The Biochemical Journal, 2025
Flat Cell Variant of Lung Adenocarcinoma In Situ.
Oka N et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.
Ghosh P et al.
Biochemical Society Transactions, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.
Park J et al.
Targeted Oncology, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
Meric-Bernstam F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world.
Li M et al.
Bmc Pulmonary Medicine, 2025
Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report.
Umeda Y et al.
Thoracic Cancer, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.
Fernandes M et al.
Febs Letters, 2023
Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
Liu JJ et al.
Hepatology (baltimore, Md.), 2023
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis.
Lu D et al.
Cancers, 2022
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Lee JK et al.
Jco Precision Oncology, 2021
Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation.
Gao B et al.
Frontiers in Medicine, 2021
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.
Lusk CM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Spatial regulation of signaling by the coordinated action of the protein tyrosine kinases MET and FER.
Zhang J et al.
Cellular Signalling, 2018
MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.
Lu X et al.
Cancer Research, 2017
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Rolle CE et al.
Oncotarget, 2017
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
Drilon A
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y et al.
Oncogene, 2015
The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
Maroun CR et al.
Pharmacology & Therapeutics, 2014
Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.
Muharram G et al.
Developmental Cell, 2014
Met endosomal signalling: in the right place, at the right time.
Barrow-McGee R et al.
The International Journal of Biochemistry & Cell Biology, 2014
Altered trafficking of mutated growth factor receptors and their associated molecules: implication for human cancers.
Kon S et al.
Cellular Logistics, 2014
Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer.
Lai AZ et al.
The Journal of Biological Chemistry, 2012
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
The MET axis as a therapeutic target.
Sattler M et al.
Update on Cancer Therapeutics, 2009
Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase.
Sangwan V et al.
The Journal of Biological Chemistry, 2008
Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway.
Mak HH et al.
Oncogene, 2007
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
Sattler M et al.
Current Oncology Reports, 2007
Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.
Abella JV et al.
Molecular and Cellular Biology, 2005
A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
Peschard P et al.
The Journal of Biological Chemistry, 2004
Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases.
Peschard P et al.
Cancer Cell, 2003
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
Peschard P et al.
Molecular Cell, 2001